Tuesday, February 23, 2021 1:14:42 PM
-No more dilutive debt
-Reports on the way
-Possible uplisting (10 years out, who knows? I don't)
-$2,000,000 in annualized earnings (maybe)
-Growth (probably)
-$0.15 share acquisition price (why you'd sell at that price, idk. volume is volume though.)
-20,000,000 shares outstanding (roughly)
-$3,000,000 market capitalization
-66% earnings yield (assuming GERS reaches $2m in annualized earnings at some point in the future, I think that's a safe assumption.)
Outcome: an increased allocation size on a long-term gamble worth making?
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM